Therapeutic drug monitoring of vancomycin in patients with infectious complications in traumatology and orthopedics

Therapeutic drug monitoring of vancomycin in patients with infectious complications in traumatology and orthopedics

Objective. The purpose of this study was to study the frequency of achievement of target values of vancomycin residual concentration (RC) and to identify the factors influencing this indicator. Materials and Methods. A retrospective observational study of vancomycin RC was performed in 471 patie...

Full description

Bibliographic Details
Main Authors:	Borisov A.M., Galankin T.L., Bozhkova S.A., Verbitskaya E.V., Kasimova A.R., Koroleva E.M.
Format:	Article
Language:	Russian
Published:	Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy 2020-03-01
Series:	Клиническая микробиология и антимикробная химиотерапия
Subjects:	vancomycin therapeutic drug monitoring residual concentration pharmacokinetics ssi
Online Access:	https://cmac-journal.ru/publication/2020/1/cmac-2020-t22-n1-p060/cmac-2020-t22-n1-p060.pdf

Similar Items

Sorting Out the Risks and Benefits of the #797 Recommended Intrapartum Vancomycin Dosing Approach
by: Andras Farkas, et al.
Published: (2022-12-01)

Assessment of Initial Vancomycin Dosing in Pediatric Oncology Patients
by: Hillary Orr, et al.
Published: (2017-08-01)

Evaluation of vancomycin individualized model-based dosing approach in neonates
by: Manal Abouelkheir, et al.
Published: (2023-05-01)

Vancomycin population pharmacokinetic modeling in children using Bayesian estimation and a Non Parametric Approach
by: Anna Luísa Oliveira Silveira, et al.
Published: (2022-06-01)

Infectious Prophylaxis with Intrawound Vancomycin Powder in Orthopedic Surgeries: Systematic Review with Meta-Analysis
by: David Sadigursky, et al.

Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration
by: Erin Chung, et al.
Published: (2021-04-01)

The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock
by: Katip W, et al.
Published: (2016-11-01)

Clinical pharmacokinetics of vancomycin in the neonate: a review
by: Gian Maria Pacifici, et al.
Published: (2012-07-01)

Pharmacokinetics and therapeutic target attainment of vancomycin in pediatric post-liver transplant patients
by: Ronaldo Morales Junior, et al.
Published: (2023-11-01)

Population Pharmacokinetics and Dosing Simulation of Vancomycin Administered by Continuous Injection in Critically Ill Patient
by: Romain Garreau, et al.
Published: (2021-10-01)

Study of antibiotic efficacy of topical vancomycin powder in treatment of infected mandibular fractures and soft tissue surgical site infections
by: Geeta Singh, et al.
Published: (2019-01-01)

Population Pharmacokinetics and Dosing Optimization of Vancomycin in Pediatric Liver Transplant Recipients
by: Kensuke Shoji, et al.
Published: (2021-10-01)

Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections
by: Kai Shen, et al.
Published: (2021-04-01)

Therapeutic Drug Monitoring for Evaluation of the Efficacy and Safety of Vancomycin in Patients with Orthopaedic Infections
by: O. S. Tufanova, et al.
Published: (2022-07-01)

Continuous-Infusion Vancomycin in Neonates: Assessment of a Dosing Regimen and Therapeutic Proposal
by: Manon Tauzin, et al.
Published: (2019-05-01)

Pharmacokinetic and Biomarker Quantification Studies on Vancomycin-Loaded PEGylated Liposomes and Its Potential to Reduce Vancomycin-Induced Kidney Injury: A Rat Study
by: Medha D. Joshi, et al.
Published: (2023-05-01)

Comparison of intermittent versus continuous-infusion vancomycin for treating severe patients in intensive care units
by: Carolina Hikari Yamada, et al.
Published: (2020-07-01)

Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment
by: Ahmed KA, et al.
Published: (2024-01-01)

Characteristics and calculations of paired vancomycin measurements for determination of 24-h area-under-curve (AUC)
by: Yutao Deng, et al.
Published: (2023-03-01)

Comparison of Intravenous Microdialysis and Standard Plasma Sampling for Monitoring of Vancomycin and Meropenem Plasma Concentrations—An Experimental Porcine Study
by: Johanne Gade Lilleøre, et al.
Published: (2023-04-01)

Dose Optimization of Vancomycin for Critically Ill Patients Undergoing CVVH: A Prospective Population PK/PD Analysis
by: Chuhui Wang, et al.
Published: (2021-11-01)

Describing vancomycin serum levels in pediatric intensive care unit (ICU) patients: are expected goals being met
by: Talita Muniz Maloni, et al.
Published: (2019-07-01)

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization
by: Kui-fen Ma, et al.
Published: (2020-10-01)

Population pharmacokinetics and individualized dosing of vancomycin for critically ill patients receiving continuous renal replacement therapy: the role of residual diuresis
by: Zhenwei Yu, et al.
Published: (2023-12-01)

Systematic review of efficacy, safety and pharmacokinetics of intravenous and intraventricular vancomycin for central nervous system infections
by: Shu-Ping Liu, et al.
Published: (2022-11-01)

Dose Tailoring of Vancomycin Through Population Pharmacokinetic Modeling Among Surgical Patients in Pakistan
by: Muhammad Muaaz Munir, et al.
Published: (2021-11-01)

Vancomycin Serum Concentration after 48 h of Administration: A 3-Years Survey in an Intensive Care Unit
by: Nicolas Perin, et al.
Published: (2020-11-01)

Bayesian method application: Integrating mathematical modeling into clinical pharmacy through vancomycin therapeutic monitoring
by: Ashley Chen, et al.
Published: (2022-12-01)

Vancomycin and daptomycin dosing recommendations in patients receiving home hemodialysis using Monte Carlo simulation
by: Susan J. Lewis, et al.
Published: (2023-09-01)

Liposomes for systematic delivery of vancomycin hydrochloride to decrease nephrotoxicity: Characterization and evaluation
by: Junli Liu, et al.
Published: (2015-06-01)

A Systematic Review of Vancomycin Dosing in Patients with Hematologic Malignancies or Neutropenia
by: He N, et al.
Published: (2020-06-01)

Application of machine learning combined with population pharmacokinetics to improve individual prediction of vancomycin clearance in simulated adult patients
by: Guodong Li, et al.
Published: (2024-03-01)

Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets
by: Nicole Bradley, et al.
Published: (2023-06-01)

Vancomycin Drug Utilization Evaluation in infectious disease ward of Imam Khomeini Hospital
by: Khalili H, et al.
Published: (2007-05-01)

What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value
by: Bruce R. Dalton
Published: (2023-02-01)

Vancomycin treatment: analysis of efficacy and safety
by: Brigita Mavsar-Najdenov, et al.
Published: (2007-11-01)

Efficacy of Vancomycin and Meropenem in Central Nervous System Infections in Children and Adults: Current Update
by: Franziska Schneider, et al.
Published: (2022-01-01)

Population Pharmacokinetics Modeling of Vancomycin Among Chinese Infants With Normal and Augmented Renal Function
by: De-Yi Li, et al.
Published: (2021-09-01)

Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling
by: Yong Kyun Kim, et al.
Published: (2022-05-01)

Rapid Colloidal Gold Immunoassay for Pharmacokinetic Evaluation of Vancomycin in the Cerebrospinal Fluid and Plasma of Beagle Dogs
by: Yechang Guo, et al.
Published: (2023-11-01)